New drug shows promise for Long-Term control of rare immune disorders
NCT ID NCT06990529
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the long-term safety of a drug called leniolisib in people with primary immunodeficiency disorders linked to PI3K signaling. Participants are 12 people who already took leniolisib in a previous study and may benefit from continuing it. The goal is to see if the drug remains safe and helps control immune problems over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- leniolisib
- What this could lead to
- If successful, this could show that leniolisib is safe and effective for long-term control of immune problems in people with certain primary immunodeficiency disorders.
- What could go wrong
- This is a small, early-phase extension study with only 12 participants, so results may not apply to everyone. Long-term side effects are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIDS LINKED TO PI3K are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IIS La Fe
RECRUITINGValencia, Spain
-
Lahey Hospital & Medical Center
RECRUITINGBurlington, Massachusetts, 01805, United States
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States